Ola Billing
YOU?
Author Swipe
View article: Stromal collagen IV expression and risk of breast cancer death in ductal carcinoma in situ
Stromal collagen IV expression and risk of breast cancer death in ductal carcinoma in situ Open
Background Current treatment for ductal carcinoma in situ (DCIS) of the breast is generic, due to lack of risk stratification tools. We investigate the correlation between expression of collagen IV in the breast and risk of dying of breast…
View article: Stromal collagen IV expression and risk of breast cancer death in ductal carcinoma in situ
Stromal collagen IV expression and risk of breast cancer death in ductal carcinoma in situ Open
Background. Current treatment for ductal carcinoma in situ (DCIS) of the breast is generic, due to lack of risk stratification tools. We investigate the correlation between expression of collagen IV in the breast and risk of breast cancer …
View article: Figure S3 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i>
Figure S3 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i> Open
Automated scoring of vulval induction and percent larvae in the ST65 strain.
View article: Supp methods and figure legends from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i>
Supp methods and figure legends from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i> Open
Supplementary methods and figure legends
View article: Figure S4 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i>
Figure S4 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i> Open
Automated scoring of larvae in the ST65 strain.
View article: Table S1 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i>
Table S1 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i> Open
Supplementary table 1. All Compounds and Exclusions
View article: Figure S1 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i>
Figure S1 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i> Open
Manual scoring of vulval induction in the ST65 strain.
View article: Figure S2 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i>
Figure S2 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i> Open
Z-factors for automated scoring protocols in the ST65 strain.
View article: Figure S4 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i>
Figure S4 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i> Open
Automated scoring of larvae in the ST65 strain.
View article: Figure S3 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i>
Figure S3 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i> Open
Automated scoring of vulval induction and percent larvae in the ST65 strain.
View article: Figure S1 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i>
Figure S1 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i> Open
Manual scoring of vulval induction in the ST65 strain.
View article: Supp methods and figure legends from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i>
Supp methods and figure legends from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i> Open
Supplementary methods and figure legends
View article: Table S1 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i>
Table S1 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i> Open
Supplementary table 1. All Compounds and Exclusions
View article: Figure 4 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i>
Figure 4 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i> Open
Evaluation of pathway specificity. A, Differential interference contrast (DIC) micrographs showing overall body morphology (inlayed panels) and vulval phenotypes in untreated lin-15(n765) and lin-1(e1777) mutant adults. Arrows indicate fun…
View article: Figure S2 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i>
Figure S2 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i> Open
Z-factors for automated scoring protocols in the ST65 strain.
View article: Figure S1 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i>
Figure S1 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i> Open
Manual scoring of vulval induction in the ST65 strain.
View article: Figure 3 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i>
Figure 3 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i> Open
Readouts for toxicity and MAPK/ERK pathway inhibition from fluorescence-based scoring. Heatmaps showing means from three independent experiments for each drug and concentration. A, Putative toxicity measured as percent larvae at time of an…
View article: Supp methods and figure legends from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i>
Supp methods and figure legends from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i> Open
Supplementary methods and figure legends
View article: Figure S4 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i>
Figure S4 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i> Open
Automated scoring of larvae in the ST65 strain.
View article: Figure 5 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i>
Figure 5 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i> Open
In silico scoring pipelines. A,In silico scoring of fluorescent foci using MetaXpress and CellProfiler software. From left, brightfield images, GFP images, and the concomitant detection mask that shows each detected feature in different co…
View article: Figure 3 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i>
Figure 3 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i> Open
Readouts for toxicity and MAPK/ERK pathway inhibition from fluorescence-based scoring. Heatmaps showing means from three independent experiments for each drug and concentration. A, Putative toxicity measured as percent larvae at time of an…
View article: Figure 5 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i>
Figure 5 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i> Open
In silico scoring pipelines. A,In silico scoring of fluorescent foci using MetaXpress and CellProfiler software. From left, brightfield images, GFP images, and the concomitant detection mask that shows each detected feature in different co…
View article: Figure 4 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i>
Figure 4 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i> Open
Evaluation of pathway specificity. A, Differential interference contrast (DIC) micrographs showing overall body morphology (inlayed panels) and vulval phenotypes in untreated lin-15(n765) and lin-1(e1777) mutant adults. Arrows indicate fun…
View article: Figure S3 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i>
Figure S3 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i> Open
Automated scoring of vulval induction and percent larvae in the ST65 strain.
View article: Figure S2 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i>
Figure S2 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i> Open
Z-factors for automated scoring protocols in the ST65 strain.
View article: Figure 6 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i>
Figure 6 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i> Open
Blinded screen identification of MAPK/ERK pathway inhibitors. A, Violin plot showing the vulvae/adult score distribution of screened compounds after applying exclusion criteria. B, Hit validation of 1° hits. The plot shows the mean values …
View article: Figure 2 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i>
Figure 2 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i> Open
Scoring of vulva tissue. A, Bar graph showing distributions of indicated phenotypes in WT N2 animals after exposure to control DMSO media (n = 244) or 10 μmol/L trametinib (n = 296). B, Nomarski and fluorescence images of the ST65 strain, …
View article: Figure 2 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i>
Figure 2 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i> Open
Scoring of vulva tissue. A, Bar graph showing distributions of indicated phenotypes in WT N2 animals after exposure to control DMSO media (n = 244) or 10 μmol/L trametinib (n = 296). B, Nomarski and fluorescence images of the ST65 strain, …
View article: Data from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i>
Data from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i> Open
Oncogenic signaling through the MAPK/ERK pathway drives tumor progression in many cancers. Although targeted MAPK/ERK pathway inhibitors improve survival in selected patients, most tumors are resistant. New drugs could be identified in sma…
View article: Table S1 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i>
Table S1 from A Drug Discovery Pipeline for MAPK/ERK Pathway Inhibitors in <i>Caenorhabditis elegans</i> Open
Supplementary table 1. All Compounds and Exclusions